Axonara Biosciences

Axonara serves to unveil the genetic etiology of patients presenting with seizures to enhance therapeutic/surgical decision-making for clinicians. We are tackling the diagnosis of several neurological conditions via the pathogenic mutations that are causal for disease, all at the point of care. We are especially focused on cerebral cavernous malformations (CCMs), and aim to raise the prevalence of genetic screening for mutations across the CCM family of genes, increasing the longevity of CCM patients globally.

Founder